Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
178
resultados
Última actualización
28/08/2026 [07:44:00]
Resultados 100 a 125 de 178
Resumen de: WO2025056518A1
The present invention relates to the field of medicinal chemistry and more specifically to 5,6- disubstituted 1H- and 2H- indazoles as pharmaceutically active compounds. The compounds of the present invention are dual inhibitors of butyrylcholinesterase and p38α mitogen-activated protein kinase, and thus are particularly useful for the treatment of various diseases which may be therapeutically modified by altering the activity of butyrylcholinesterase (BChE) and/or p38α MAP kinase such as dementias including Alzheimer's disease (AD) and other conditions involving chronic inflammation.
Resumen de: US20260199270A1
Provided herein are methods for treating Alzheimer's disease using a combination of tramiprosate, a tramiprosate prodrug or an active tramiprosate metabolite with at least one amyloid plaque clearing agent.
Resumen de: US20260199232A1
A polymer layer containing a pharmaceutical drug substance-loaded amino group and a nanomotor containing a metal layer for orientation by a magnetic field is used to treat Alzheimer's Disease; Memantine HCl-loaded nanomotors are synthesized with a biocompatible poly-L-lysine polymer whose movement is directly controlled by the magnetic field and targets the brain by crossing the blood brain barrier by providing movement in the magnetic field.
Resumen de: US20260199527A1
0000 Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.
Resumen de: AU2026204876A1
The present disclosure provides compositions and methods for modulating transcription of mutant C9orf72 gene alleles in patients in need thereof, including patients having a C9orf72-related disease such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). un u n
Resumen de: US20260201026A1
0000 The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.
Resumen de: AU2026204572A1
The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer disease (EOFAD or eFAD), using such dsRNAi agents and compositions. un u n
Resumen de: US20260201025A1
The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.
Resumen de: AU2025210321A1
This invention provides a method of prolonging the survival of subjects afflicted with ALS by administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof.
Resumen de: AU2024403764A1
The present disclosure is directed to compounds of Formula (I) and their use as TREM2 agonists for treatment and prevention of a neurodegenerative disorder associated with a loss of function of human TREM2. The disclosed TREM2 agonists may be useful for the treatment of Alzheimer's Disease and associated neurological conditions.
Resumen de: AU2024406047A1
The present disclosure is directed to compounds of Formula I and their use as TREM2 agonists for treatment and prevention of a neurodegenerative disorder associated with a loss of function of human TREM2. The disclosed TREM2 agonists may be useful for the treatment of Alzheimer's Disease and associated neurological conditions.
Resumen de: AU2024400795A1
Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.
Resumen de: WO2026151017A1
The compound represented by chemical formula IA according to the present invention is useful for the prevention, alleviation, and treatment of degenerative brain diseases.
Resumen de: WO2026148417A1
Disclosed herein are methods of using epertinib in the treatment of neurological conditions such as ALS.
Resumen de: WO2026151983A1
Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and/or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on methods of identifying a subject of having or being at risk of developing a disease or disorder associated with dysregulated glutamine levels, such as a subject having a mutation that affects glutaminase (GLS1), which is an enzyme responsible for producing glutamate from glutamine. In some embodiments, compositions and methods of the disclosure are useful for treating a psychiatric disorder (e.g., depression (DEP), major depressive disorder (MDD), bipolar disorder (e.g., BPD1, BPD2), mania (MAN), psychosis (PSY), schizophrenia (SCZ), schizoaffective disorder (SZA), or post-traumatic stress disorder (PTSD)) and/or a disease associated with dementia, such as Alzheimer's disease.
Resumen de: US20260201390A1
The present disclosure provides compositions and methods for the treatment of levodopa-induced dyskinesia (LID) and Parkinson's disease (PD) therewith. In particular, the present disclosure provides methods for treating LID in PD by inhibiting (e.g., expression of) Muscarinic M1 acetylcholine receptor (M1Rs), for example, in indirect pathway spiny projection neurons (iSPNs) to attenuate LID without compromising of the treatment with levodopa (e.g., boosting the efficacy of levodopa treatment).
Resumen de: US20260199329A1
0000 The subject invention pertains to a composition comprising a series of compounds selectively targeting G-quadruplexes (G4s) formed by the GGGGCC (G4C2) hexanucleotide repeats (HREs) of C9orf72, (G4C2)
Resumen de: WO2026148695A1
The present invention relates to the technical field of medicines, and specifically relates to a deuterated huperzine A compound or a pharmaceutically acceptable salt thereof, and a preparation method therefor and a use thereof. The structure of the deuterated huperzine A compound is as follows, wherein R1-R9 are each independently H or D, and are not both H. The present invention has the advantages of high chemical stability, long metabolic half-life, low toxicity, significant synergistic effect with bremelanotide in the treatment of Alzheimer's disease, and ability to reduce the toxicity of bremelanotide.
Resumen de: US20260200848A1
The present disclosure describes crystalline forms of 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts and pharmaceutical compositions of same. Also described are methods of using the crystalline forms treating Alzheimer's Disease, Dementia with Lewy Bodies and Dry age-related macular degeneration in a subject in need thereof, comprising administering the crystalline form to the subject. Methods of making the solid forms are also described.
Resumen de: US20260199365A1
Provided are compounds and pharmaceutically acceptable salt, solvate and/or derivative thereof. Further, provided are methods of treating a disease, disorder or condition mediated or treatable by activation of SHIP1 comprising administering a SHIP1 activator compound or a pharmaceutically acceptable salt, solvate or derivative thereof. The compound or a pharmaceutically acceptable salt, solvate or derivative thereof may be used in the treatment of SHIP1 mediated disease, disorder or conditions including inflammatory bowel disease (IBD), Crohn′ disease, COPD, ulcerative colitis, arthritis, and Alzheimer's Disease.
Resumen de: EP4775668A2
The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).
Resumen de: WO2025052129A1
The invention relates to compounds of formula (I): and related aspects. The compounds are inhibitors of mPTP.
Resumen de: EP4775203A1
The present invention relates to a vanillic acid derivative compound, which may be formed by a dehydration condensation reaction between vanillic acid and a catecholamine. The vanillic acid derivative compound according to the present invention is characterized in that it can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation.Also, the present invention relates to a pharmaceutical composition for treating Alzheimer's disease and a pharmaceutical composition for treating neuroinflammation, each comprising the above compound.
Resumen de: US20260191889A1
The present disclosure relates to compositions comprising trehalose and methods of using same for the treatment of Huntington's disease.
Nº publicación: US20260191871A1 09/07/2026
Solicitante:
EPIPHANY BIOSCIENCES [US]
EPIPHANY BIOSCIENCES
Resumen de: US20260191871A1
0000 The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.
BOPI
Sede Electrónica
